Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-65
SponsorVanda Pharmaceuticals
About this trial
An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis
Eligibility criteria
Qualifiers
Male and female subjects aged 18-65 years, inclusive
BMI >18 and <40
Minimum affected BSA of 10%
PASI score ≥ 12
Disqualifiers
Diagnosis of generalized erythrodermic, generalized pustular (von Zumbusch), guttate, or palmoplantar psoriasis
History of an allergic reaction or known and/or significant sensitivity to study drug
Trial design
Treatments tested in this trial
- Ponesimod
Treatment groups
300 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov